US equities |
INTC $66.22 ▼-28.08% AMZN $241.31 ▼-1.02% MU $890.92 ▼-4.64% NVDA $206.57 ▼-3.32% GOOGL $282.36 ▼-0.51% SNDK $1,192.26 ▼-10.36% SPCX $138.29 ▼-3.89% AMD $513.80 ▼-9.29%
FinancialContent

(OP:LADX)

0.0110 UNCHANGED
Delayed Quote Updated: 3:47 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LADX

News headline image
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 ↗
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production. 
Via Benzinga
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
From LadRx Corporation
Via Business Wire
News headline image
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
From LadRx Corporation
Via Business Wire
News headline image
LadRx Issues 2024 Update to Shareholders
From LadRx Corporation
Via Business Wire
News headline image
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
From LadRx Corporation
Via Business Wire
News headline image
LadRx Announces Reverse Stock Split Effective as of May 17, 2023
From LadRx Corporation
Via Business Wire
News headline image
LadRx Announces Reverse Stock Split
From LadRx Corporation
Via Business Wire
News headline image
LadRx Highlights Patent Issued for Its LADR Technology
From LadRx Corporation
Via Business Wire
News headline image
LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates
From LadRx Corporation
Via Business Wire
News headline image
LadRx Corporation Issues Corporate Update for 3Q22
From LadRx Corporation
Via Business Wire